Ferric carboxymaltose IV
Phase 3Small molecule
Ferric carboxymaltose IV is one of 12 small molecule programs targeting Scoliosis. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
15 competitors in Scoliosis
#DrugCompanyPhaseTrials
1MS Contin
HHikma Pharmaceuticals LLC
Approved
Cyklokapron
JJ Molner
Approved
Marcaine
IInnocoll
Approved
Spravato
WWim Janssens
Approved
Cleviprex
Chiesi Farmaceutici S.p.A.Approved
Catapres
Boehringer IngelheimApproved
Tegileridine
XXin Chen
Phase 3
Ferric carboxymaltose IV
AAssistance Publique - Hôpitaux de Paris
Phase 3
Anerem
AAcacia Pharma Ltd
Preclinical
Plasmalyte
SSeoul National University Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Scoliosis1 trial
IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study
Recruiting·—·Phase 2/3·NCT07217873·120 enrolled
Postpartum Depression (PPD)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ferric carboxymaltose IV. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details